| Literature DB >> 28183338 |
Gui Tran1, Elizabeth M A Hensor1,2, Aaron Ray1, Sarah R Kingsbury1, Philip O'Connor1,2, Philip G Conaghan3,4,5.
Abstract
BACKGROUND: Ultrasound is increasingly used to evaluate shoulder pain, but the benefits of this are unclear. In this study, we examined whether ultrasound-defined pathologies have implications for clinical outcomes.Entities:
Keywords: Biomarkers; Pain assessment and management; Shoulder pain; Soft tissue rheumatism; Ultrasound scan
Mesh:
Year: 2017 PMID: 28183338 PMCID: PMC5304553 DOI: 10.1186/s13075-017-1235-y
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Demographics and ultrasound findings in patients included in the full scan review and those sent a questionnaire
| Full scan review ( | Questionnaire recipients ( | Responders ( | Non-responders ( | |
|---|---|---|---|---|
| Age, years, mean (SD) | 54.6 (15.1) | 54.1 (15.1) | 56.4 (13.8) | 53.0 (15.6) |
| Female sex, % | 52% | 52% | 54% | 51% |
| Pain duration, months, median (IQR) | 5 (3–9), | 5 (3–10), | 5 (3–10), | 5 (3–9), |
| Steroid injection at time of scan, % | 33% | 31% | 37% | 28% |
| RC tear, % | 26% | 24% | 27% | 23% |
| Full thickness RC tear, % | 19% | 18% | 20% | 17% |
| Bursitis, % | 68% | 71% | 72% | 71% |
| Impingement, % | 69% (of 2992) | 68% (of 2314) | 71% (of 776) | 67% (of 1538) |
| Calcific tendinitis, % | 12% | 12% | 14% | 12% |
| ACJ degeneration, % | 40% | 45% | 48% | 43% |
| Glenohumeral OA, % | 6% | 5% | 5% | 6% |
| Adhesive capsulitis, % | 3% | 3% | 4% | 3% |
| Biceps tenosynovitis, % | 7% | 9% | 9% | 9% |
| Rotator cuff tendinopathy, % | 36% | 38% | 40% | 37% |
ACJ Acromioclavicular joint, OA Osteoarthritis, RC Rotator cuff
Demographic characteristics and ultrasound pathology findings in each of four pathology groups
| Bursitis (limited inflammation) ( | Bursitis (extensive inflammation) ( | RC tear ( | Limited pathology ( | |
|---|---|---|---|---|
| Percentage of sample | 43% | 20% | 18% | 19% |
| Age, years, mean (SD) | 47.6 (11.5) | 64.2 (10.5) | 69.1 (11.2) | 46.1 (13.5) |
| Female sex, % | 54 | 52 | 51 | 46 |
| Pain duration, months,a median (IQR) | 5 (3–10) | 5 (3–9) | 5 (3–9) | 4 (3–8) |
| Steroid injection at time of scan, % | 44 | 37 | 13 | 26 |
| RC tear, yes/no, % | 2 | 24 | 100 | 6 |
| Full-thickness RC tear, % | 1 | 13 | 86 | <1 |
| Bursitis, % | 100 | 94 | 30 | 7 |
| Impingement, % | 88 | 65 | 91 | 6 |
| Calcific tendinitis, % | 14 | 18 | 5 | 9 |
| ACJ degeneration, % | 26 | 83 | 54 | 15 |
| Glenohumeral OA, % | <1 | 10 | 16 | 2 |
| Adhesive capsulitis, % | <1 | 3 | <1 | 12 |
| Biceps tenosynovitis, % | <1 | 25 | 10 | 2 |
| Rotator cuff tendinopathy, % | 23 | 92 | 24 | 20 |
| Probability of membership, mean | 0.88 | 0.80 | 0.89 | 0.93 |
ACJ Acromioclavicular joint, OA Osteoarthritis, RC Rotator cuff
a n = 507, 198, 233 and 227 in groups 1–4, respectively
Fig. 1Pathology count by group. RC Rotator cuff, US Ultrasound
Questionnaire outcomes summarised by pathology group, excluding those reporting rheumatoid arthritis (n = 690)
| Bursitis (limited inflammation) ( | Bursitis (extensive inflammation) ( | RC tear ( | Limited pathology ( | |
|---|---|---|---|---|
| Percentage of sample | 40% | 39% | 33% | 42% |
| Age, years, mean (SD) | 49.9 (11.1) | 64.8 (9.2) | 67.1 (10.4) | 47.5 (12.6) |
| Female sex, % | 63 | 45 | 47 | 55 |
| Smoker, % | 40 | 39 | 33 | 42 |
| Comorbidity count, median (IQR) | 1 (0–2) | 2 (1–2) | 2 (1–3) | 1 (0–2) |
| Painful sites count (including target), median (IQR) | 3 (1–6) | 3 (1–7) | 3 (1–6) | 2 (1–4) |
| Follow-up, months, median (IQR) | 26 (23–29) | 26 (22–29) | 25 (23–29) | 24 (21–26) |
| Had shoulder fracture before scan, % | 2 | 2 | <1 | 1 |
| Had shoulder dislocation before scan, % | 1 | – | 4 | 1 |
| Had breast/shoulder cancer before scan, % | <1 | – | – | – |
| Had major injury to target shoulder before scan, % | 7 | 8 | 18 | 3 |
| Had shoulder fracture since scan, % | <1 | 1 | – | 1 |
| Had shoulder dislocation since scan, % | <1 | – | – | – |
| Had breast/shoulder cancer since scan, % | <1 | <1 | – | – |
| Had major injury to target shoulder since scan, % | 1 | 2 | 7 | 1 |
| Had physiotherapy since scan, % | 65 | 62 | 59 | 58 |
| Had injection since scan, % | 76 | 67 | 48 | 61 |
| Had more than one injection since scan, % | 33 | 30 | 22 | 24 |
| Had surgery since scan, % | 23 | 21 | 28 | 16 |
| Still has shoulder pain, % | 63 | 63 | 77 | 64 |
| If still in pain | ||||
| Pain duration, months, median (IQR) | 24 (12–36) | 21 (12–36) | 25 (12–36) | 24 (18–36) |
| Has pain-free periods, % | 70 | 77 | 72 | 77 |
| Experiences pain on moving in a certain way, % | 91 | 93 | 92 | 85 |
| If not still in pain | ||||
| How long since last had pain, months, median (IQR) | 12 (6–17) | 13 (12–20) | 12 (6–18) | 12 (10–20) |
| How long did pain last, months, median (IQR) | 9 (3–15) | 9 (5–18) | 12 (12–18) | 6 (4–12) |
| Symptoms at time of questionnaire | ||||
| SPADI pain, median (IQR) | 34 (4–62) | 26 (2–62) | 48 (18–66) | 32 (6–64) |
| SPADI difficulty, median (IQR) | 13 (0–45) | 14 (0–43) | 30 (10–54) | 9 (0–38) |
| SPADI total, median (IQR) | 24 (3–52) | 21 (3–51) | 41 (15–59) | 25 (5–49) |
| Shoulder activity score, median (IQR) | 6 (3–10) | 6 (3–10) | 5 (3–9) | 7 (4–11) |
| EQ-5D health index score, median (IQR) | 0.8 (0.6–0.8) | 0.7 (0.6–0.8) | 0.7 (0.5–0.8) | 0.8 (0.7–0.8) |
| EQ-5D VAS, median (IQR) | 80 (55–90) | 80 (60–90) | 75 (60–80) | 80 (70–90) |
| EQ-5D anxiety or depression (>0), % | 34 | 30 | 40 | 29 |
| Depression reported in comorbidity list, % | 17 | 14 | 18 | 14 |
| Difficulty standing from sitting (>1), % | 16 | 20 | 21 | 10 |
EQ-5D EuroQol five dimensions scale, SPADI Shoulder Pain and Disability Index, VAS Visual analogue scale
Data were not available for all outcomes for all survey responders; see Additional file 1: Table S8 for numbers of patients with data available
Age- and sex-adjusted comparisons between pathology groups for key outcomes, excluding those reporting rheumatoid arthritis (n = 690)
| Bursitis (limited inflammation) ( | Bursitis (extensive inflammation) ( | RC tear ( | Limited pathology ( | Test result, | |
|---|---|---|---|---|---|
| Number of painful sitesa | 4.0 (3.7–4.2) | 4.2 (3.9–4.6) | 3.6 (3.3–4.0) | 3.0 (2.6–3.3) | χ2 = 29.0, |
| Steroid injection at time of scan | 0.49 (0.42–0.55) | 0.40 (0.32–0.47) | 0.12 (0.06–0.18) | 0.34 (0.24–0.44) | χ2 = 40.1, |
| Steroid injection since scan | 0.76 (0.70–0.81) | 0.67 (0.69–0.75) | 0.49 (0.39–0.59) | 0.63 (0.52–0.73) | χ2 = 20.3, |
| Physiotherapy | 0.59 (0.53–0.66) | 0.67 (0.60–0.75) | 0.67 (0.58–0.76) | 0.53 (0.43–0.63) | χ2 = 5.0, |
| Surgery | 0.19 (0.15–0.24) | 0.25 (0.18–0.33) | 0.35 (0.25–0.46) | 0.14 (0.07–0.21) | χ2 = 10.5, |
| Pain at follow-up | 0.59 (0.53–0.65) | 0.68 (0.61–0.75) | 0.81 (0.74–0.88) | 0.60 (0.50–0.70) | χ2 = 17.3, |
| SPADI painb | 29 (22–36) | 32 (23–41) | 51 (40–62) | 28 (17–40) |
|
| SPADI difficultyb | 15 (10–20) | 19 (12–25) | 31 (23–39) | 11 (3–20) |
|
| SPADI totalb | 23 (18–29) | 25 (18–32) | 42 (34–51) | 20 (11–29) |
|
RC Rotator cuff, SPADI Shoulder Pain and Disability Index
All values in the table are adjusted probability of the outcome (95% CI) unless otherwise stated
aAdjusted mean (95% CI)
bAdjusted median (95% CI)
Fig. 2Shoulder Pain and Disability Index (SPADI) boxplot. RC Rotator cuff